Long-term survival data from DESTINY-Breast03 trial
![](https://www.fondazionemichelangelo.org/wp-content/uploads/2022/12/News_1-1024x614.jpg)
With a longer follow-up of 41 months, trastuzumab-deruxtecan continues to demonstrate superior efficacy over trastuzumab-emtansine in HER2+ metastatic breast cancer
Tumor-infiltrating lymphocytes in triple-negative breast cancer
![](https://www.fondazionemichelangelo.org/wp-content/uploads/2022/12/AdobeStock_302042936-1536x922-1-1024x615.jpeg)
A retrospective analysis of patients treated with locoregional therapy but without adjuvant or neoadjuvant chemotherapy shows that a higher TIL abundance is associated with better survival
Chemotherapy de-escalation in HER2+ early breast cancer
![](https://www.fondazionemichelangelo.org/wp-content/uploads/2024/04/08Apr24.jpg)
A PET-based, pathological complete response-adapted strategy leads to excellent 3-year invasive disease-free survival, with a third of patients who can safely omit chemotherapy
Giredestrant in HR+/HER2- advanced breast cancer
![](https://www.fondazionemichelangelo.org/wp-content/uploads/2023/10/FM_30Oct23-1024x614.jpg)
In the phase II aceIERA trial, giredestrant was well tolerated and showed a trend toward favorabile benefit among ESR-1 mutated tumors
Effects of palbociclib and avelumab added to fulvestrant in HR+/HER2- metastatic breast cancer
![](https://www.fondazionemichelangelo.org/wp-content/uploads/2024/01/Depositphotos_11045917_XL-1024x614.jpg)
Addition of palbociclib to fulvestrant did not improve progression-free survival, whereas addition of palbociclib and avelumab had positive effects: results of the PACE trial
In memoriam of Pinuccia Valagussa
![](https://www.fondazionemichelangelo.org/wp-content/uploads/2024/05/PV_Bn-1024x1021.jpg)
With the passing of Pinuccia Valagussa, co-founder of the Michelangelo Foundation, the field of medicine loses one of the key figures of a season that set the stage of modern clinical oncology
Breast cancer treatment with PARP inhibitors, efficacy and future of research
![](https://www.fondazionemichelangelo.org/wp-content/uploads/2023/04/iStock-1254386936_2500-1024x614.jpg)
A new review from Italian researchers summarizes evidence of efficacy of PARP inhibitors, focusing on potential new applications and the future of clinical research with these agents
Effects of neoadjuvant-adjuvant pertuzumab in HER2- positive early breast cancer
![](https://www.fondazionemichelangelo.org/wp-content/uploads/2024/04/08Apr24.jpg)
The final analysis of phase III PEONY trial confirms a positive benefit/risk ratio of neoadjuvant/adjuvant pertuzumab, trastuzumab, and docetaxel treatment in patients with HER2+ early breast cancer
Ribociclib plus hormone therapy improves outcomes in early stage HR+/HER2- breast cancer
![](https://www.fondazionemichelangelo.org/wp-content/uploads/2023/04/04Apr23.jpg)
Results from the NATALEE trial show disease-free survival benefits with ribociclib added to aromatase inhibitors compared to hormone therapy alone
Inavosilib in HR+/HER2- locally advanced or metastatic breast cancer
![](https://www.fondazionemichelangelo.org/wp-content/uploads/2024/01/Depositphotos_11045917_XL-1024x614.jpg)
INAVO120 trial primary analysis shows benefits with inavosilib added to palbociclib and fulvestrant in PIK3CA-mutant locally advanced or metastatic breast cancer